Gene Therapy offers real hope to people affected by LCA RDH12. It is one of the most promising frontiers of modern medicine and involves injecting a healthy copy of the missing gene in the eye.
In 2018 the first Gene Therapy for LCA (gene RP65) was approved in the USA and Europe and showed successful sight restoration in the treated patients.
This is not available for the RDH12 gene but it means that there IS concrete hope. Our goal is for Gene Therapy to be accessible to more patients with LCA including RDH12.
Eyes on the Future is partnering with the key academic and industry partners working on RDH12 gene therapy.